{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:00:51Z","timestamp":1788303651391,"version":"build-2803163510"},"reference-count":28,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.ijrobp.2023.03.046","type":"journal-article","created":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T21:47:04Z","timestamp":1679003224000},"page":"64-73","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Pegylated Liposomal Mitomycin C Lipidic Prodrug in Combination With External Beam Radiation Therapy in Patients With Advanced Cancer: A Phase 1B Study"],"prefix":"10.1016","volume":"117","author":[{"given":"Eli","family":"Sapir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Pfeffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Wygoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ofer","family":"Purim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adi","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Corn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmine","family":"Amitay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Ohana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Gabizon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2023.03.046_bib0001","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0305-7372(76)80019-9","article-title":"Mitomycin C: A review","volume":"3","author":"Crooke","year":"1976","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ijrobp.2023.03.046_bib0002","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/00001813-199010000-00002","article-title":"Mitomycin C: Mechanism of action, usefulness and limitations","volume":"1","author":"Verweij","year":"1990","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.ijrobp.2023.03.046_bib0003","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/0360-3016(91)90102-A","article-title":"Radiosensitizing and cytotoxic properties of mitomycin C in a C3H mouse mammary carcinoma in vivo","volume":"20","author":"Grau","year":"1991","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.03.046_bib0004","first-page":"73","article-title":"Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells","volume":"41","author":"Teicher","year":"1981","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijrobp.2023.03.046_bib0005","first-page":"501","article-title":"Mitomycin C: A prototype bioreductive agent","volume":"6","author":"Sartorelli","year":"1994","journal-title":"Oncol Res"},{"key":"10.1016\/j.ijrobp.2023.03.046_bib0006","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.ijrobp.2017.03.022","article-title":"Capecitabine with mitomycin reduces acute hematologic toxicity and treatment delays in patients undergoing definitive chemoradiation using intensity modulated radiation therapy for anal cancer","volume":"98","author":"Goodman","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.03.046_bib0007","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa1106106","article-title":"Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer","volume":"366","author":"James","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2023.03.046_bib0008","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1200\/JCO.1997.15.1.268","article-title":"Chemotherapy as an adjunct to radiation in the treatment of squamous cell carcinoma of the head and neck: Results of the Yale mitomycin randomized trials","volume":"15","author":"Haffty","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.03.046_bib0009","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0360-3016(93)90234-M","article-title":"Mitomycin C as an adjunct to postoperative radiation therapy in squamous cell carcinoma of the head and neck: Results from two randomized clinical trials","volume":"27","author":"Haffty","year":"1993","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.03.046_bib0010","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ijrobp.2004.07.730","article-title":"Concurrent chemo-radiotherapy with mitomycin C compared with porfiromycin in squamous cell cancer of the head and neck: Final results of a randomized clinical trial","volume":"61","author":"Haffty","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.03.046_bib0011","first-page":"123","article-title":"Postoperative concurrent chemoradiotherapy with mitomycin in advanced squamous cell carcinoma of the head and neck: Results from three prospective randomized trials","volume":"12","author":"Rewari","year":"2006","journal-title":"Cancer J"},{"key":"10.1016\/j.ijrobp.2023.03.046_bib0012","first-page":"1339","article-title":"Suppression of P-glycoprotein expression and multidrug resistance by DNA cross-linking agents","volume":"3","author":"Ihnat","year":"1997","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2023.03.046_bib0013","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0167-8140(87)80020-8","article-title":"Mitomycin C-induced hemolytic uremic syndrome. Six case reports and review of the literature on renal, pulmonary and cardiac side effects of the drug","volume":"8","author":"Verweij","year":"1987","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2023.03.046_bib0014","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.5414\/CP202129","article-title":"A statistical analysis to assess the most critical bioequivalence parameters for generic liposomal products","volume":"52","author":"Hsu","year":"2014","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.ijrobp.2023.03.046_bib0015","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.addr.2012.10.002","article-title":"The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo","volume":"65","author":"Maeda","year":"2013","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"10.1016\/j.ijrobp.2023.03.046_bib0016","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jconrel.2011.11.019","article-title":"Therapeutic efficacy of a lipid-based prodrug of mitomycin C in pegylated liposomes: studies with human gastro-entero-pancreatic ectopic tumor models","volume":"160","author":"Gabizon","year":"2012","journal-title":"J Control Release."},{"key":"10.1016\/j.ijrobp.2023.03.046_bib0017","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.addr.2020.07.027","article-title":"Development of Promitil\u00ae, a lipidic prodrug of mitomycin c in PEGylated liposomes: From bench to bedside","volume":"154-155","author":"Gabizon","year":"2020","journal-title":"Adv Drug Deliv Rev"},{"issue":"6","key":"10.1016\/j.ijrobp.2023.03.046_bib0018","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1158\/1078-0432.CCR-05-1547","article-title":"Reduced toxicity and superior therapeutic activity of a mitomycin C lipid-based prodrug incorporated in pegylated liposomes","volume":"12","author":"Gabizon","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.ijrobp.2023.03.046_bib0019","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1007\/s11095-015-1819-7","article-title":"Pharmacologic Studies of a Prodrug of Mitomycin C in Pegylated Liposomes (Promitil(\u00ae)): High Stability in Plasma and Rapid Thiolytic Prodrug Activation in Tissues","volume":"33","author":"Amitay","year":"2016","journal-title":"Pharm Res"},{"issue":"10","key":"10.1016\/j.ijrobp.2023.03.046_bib0020","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1002\/cam4.491","article-title":"Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patients","volume":"4","author":"Golan","year":"2015","journal-title":"Cancer Medicine"},{"issue":"5","key":"10.1016\/j.ijrobp.2023.03.046_bib0021","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1007\/s10637-020-00897-3","article-title":"Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patients,","volume":"38","author":"Gabizon","year":"2020","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.ijrobp.2023.03.046_bib0022","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2023.03.046_bib0023","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","article-title":"Randomized trial of TAS-102 for refractory metastatic colorectal cancer","volume":"372","author":"Mayer","year":"2015","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ijrobp.2023.03.046_bib0024","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ijrobp.2016.06.2457","article-title":"Preclinical Evaluation of Promitil, a Radiation-Responsive Liposomal Formulation of Mitomycin C Prodrug, in Chemoradiotherapy","volume":"96","author":"Tian","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.03.046_bib0025","doi-asserted-by":"crossref","first-page":"544","DOI":"10.3389\/fonc.2018.00544","article-title":"Chemo-Radiotherapy of Oligometastases of Colorectal Cancer With Pegylated Liposomal Mitomycin-C Prodrug (Promitil): Mechanistic Basis and Preliminary Clinical Experience","volume":"8","author":"Tahover","year":"2018","journal-title":"Front Oncol"},{"key":"10.1016\/j.ijrobp.2023.03.046_bib0026","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1259\/0007-1285-62-740-679","article-title":"The linear-quadratic formula and progress in fractionated radiotherapy","volume":"62","author":"Fowler","year":"1989","journal-title":"Br J Radiol"},{"key":"10.1016\/j.ijrobp.2023.03.046_bib0027","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/BF00685879","article-title":"Pharmacokinetics of BW12C and mitomycin C, given in combination in a phase 1 study in patients with advanced gastrointestinal cancer","volume":"32","author":"Dennis","year":"1993","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ijrobp.2023.03.046_bib0028","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.addr.2013.11.009","article-title":"Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology","volume":"66","author":"Bertrand","year":"2014","journal-title":"Adv Drug Deliv Rev"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301623002870?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301623002870?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T10:09:05Z","timestamp":1759745345000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301623002870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S0360301623002870"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2023.03.046","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pegylated Liposomal Mitomycin C Lipidic Prodrug in Combination With External Beam Radiation Therapy in Patients With Advanced Cancer: A Phase 1B Study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2023.03.046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}